Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Doxorubicin

Doxorubicin Reactions 1704, p147 - 2 Jun 2018 Cardiotoxicity: 15 case reports In a study, 15 patients (10 male and 5 female) aged between 12 67 years were described, who developed anthracyclines- related cardiotoxicity following treatment with chemotherapy regimens containing an anthracycline, doxorubicin [adriamycin, hydroxydaunorubicin] for malignant lymphomas [routes, exact dosages and durations of treatments to reactions onsets not stated]. All the patients, who had stage 1 4 malignant lymphoma (follicular lymphoma, diffuse large B-cell lymphoma or Hodgkin’s lymphoma), received various doxorubicin- containing chemotherapy regimens. Of these, 11 patients received CHOP regimen comprising doxorubicin, cyclophosphamide, vincristine and prednisone, 3 patients received ABVD regimen containing doxorubicin, bleomycin, vinblastine and dacarbazine, and the remaining one patient received Hybrid regimen containing doxorubicin. The total doxorubicin dose administered during chemotherapy ranged between 150 400 [unit not stated]. During or after chemotherapy, a decrease in the ejection fraction was reported in all the patients. A subsequent ECGs of six of these patients showed ST-T changes, while ECGs of the remaining nine patients were normal. A diagnosis of anthracyclines- induced cardiotoxicity was made. The status of cardiotoxicity was acute in 14 patients and it was found to be chronic in 1 patient. Out of 15 patients, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Doxorubicin

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Doxorubicin

Abstract

Reactions 1704, p147 - 2 Jun 2018 Cardiotoxicity: 15 case reports In a study, 15 patients (10 male and 5 female) aged between 12 67 years were described, who developed anthracyclines- related cardiotoxicity following treatment with chemotherapy regimens containing an anthracycline, doxorubicin [adriamycin, hydroxydaunorubicin] for malignant lymphomas [routes, exact dosages and durations of treatments to reactions onsets not stated]. All the patients, who had stage 1 4 malignant lymphoma...
Loading next page...
 
/lp/springer_journal/doxorubicin-R8l61W62zg
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46790-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p147 - 2 Jun 2018 Cardiotoxicity: 15 case reports In a study, 15 patients (10 male and 5 female) aged between 12 67 years were described, who developed anthracyclines- related cardiotoxicity following treatment with chemotherapy regimens containing an anthracycline, doxorubicin [adriamycin, hydroxydaunorubicin] for malignant lymphomas [routes, exact dosages and durations of treatments to reactions onsets not stated]. All the patients, who had stage 1 4 malignant lymphoma (follicular lymphoma, diffuse large B-cell lymphoma or Hodgkin’s lymphoma), received various doxorubicin- containing chemotherapy regimens. Of these, 11 patients received CHOP regimen comprising doxorubicin, cyclophosphamide, vincristine and prednisone, 3 patients received ABVD regimen containing doxorubicin, bleomycin, vinblastine and dacarbazine, and the remaining one patient received Hybrid regimen containing doxorubicin. The total doxorubicin dose administered during chemotherapy ranged between 150 400 [unit not stated]. During or after chemotherapy, a decrease in the ejection fraction was reported in all the patients. A subsequent ECGs of six of these patients showed ST-T changes, while ECGs of the remaining nine patients were normal. A diagnosis of anthracyclines- induced cardiotoxicity was made. The status of cardiotoxicity was acute in 14 patients and it was found to be chronic in 1 patient. Out of 15 patients,

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

References

  • Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity.
    Vinodhini, MT